The RRM2 gene has been introduced as an oncogene in several cancers, including CRC, so its increased expression is associated with advanced tumor grade, poor prognosis, and reduced patient survival, and its inhibition through the induction of cell apoptosis can be a potential therapeutic strategy for CRC [40–43]. The gene discussed is RRM2; the disease is cancer.